Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma

Blood

Volumn 115, Issue 3, 2010, Pages 601-604

  Reijmers, Rogier M ^a   Groen, Richard W J ^a,b   Rozemuller, Henk ^b   Kuil, Annemieke ^a   De Haan Kramer, Anneke ^a   Csikós, Tamás ^a   Martens, Anton C M ^b   Spaargaren, Marcel ^a   Pals, Steven T ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARAN SULFATE; PROTEIN EXT1; PROTEOHEPARAN SULFATE; RAG2 PROTEIN; SYNDECAN 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DOXYCYCLINE; EXOSTOSIN 1; EXOSTOSIN-1; IMMUNOGLOBULIN HEAVY CHAIN; N ACETYLGLUCOSAMINYLTRANSFERASE; RAG2 PROTEIN, MOUSE; SDC1 PROTEIN, MOUSE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOSYNTHESIS; BONE MARROW; CELL SURVIVAL; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; RNA INTERFERENCE; TUMOR GROWTH; TUMOR LOCALIZATION; XENOTRANSPLANTATION; ANIMAL; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; DOXYCYCLINE; DRUG DELIVERY SYSTEMS; GENE TARGETING; HEPARITIN SULFATE; HUMANS; IMMUNOGLOBULIN GAMMA-CHAINS; MICE; MICE, KNOCKOUT; MULTIPLE MYELOMA; N-ACETYLGLUCOSAMINYLTRANSFERASES; RNA, SMALL INTERFERING; SYNDECAN-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77449107154     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-204396     Document Type: Article

References (25)

1. Wijdenes J, Vooijs WC, Clément C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol. 1996; 94(2):318-323.
2. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585-598.
3. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2(3):175-187.
4. Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites of heparan sulfate. Annu Rev Biochem. 2002;71:435-471.
5. Lindahl U. Heparan sulfate-protein interactions: a concept for drug design? Thromb Haemost. 2007;98(1):109-115.
6. Kramer KL, Yost HJ. Heparan sulfate core proteins in cell-cell signaling. Annu Rev Genet. 2003; 37:461-484.
7. Morgan MR, Humphries MJ, Bass MD. Synergistic control of cell adhesion by integrins and syndecans. Nat Rev Mol Cell Biol. 2007;8(12):957-969.
8. Yoneda A, Couchman JR. Regulation of cytoskeletal organization by syndecan transmembrane proteoglycans. Matrix Biol. 2003;22(1):25-33.
9. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007;446(7139):1030-1037.
10. Børset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood. 2000;96(7):2528-2536.
11. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood. 2002;99(4):1405-1410.
12. Mahtouk K, Cremer FW, Rème T, et al. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene. 2006;25(54):7180-7191.
13. Yang Y, MacLeod V, Dai Y, et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood. 2007;110(6):2041- 2048.
14. Derksen PW, de Gorter DJ, Meijer HP, et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia. 2003;17(4):764-774.
15. Derksen PW, Tjin E, Meijer HP, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A. 2004; 101(16):6122-6127.
16. Tjin EP, Derksen PW, Kataoka H, Spaargaren M, Pals ST. Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood. 2004; 104(7):2172-2175.
17. Alexander CM, Reichsman F, Hinkes MT, et al. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet. 2000; 25(3):329-332.
18. Beauvais DM, Burbach BJ, Rapraeger AC. The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J Cell Biol. 2004;167(1):171-181.
19. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer. 2002;2(7):521-528.
20. Lind T, Tufaro F, McCormick C, Lindahl U, Lidholt K. The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem. 1998;273(41):26265-26268.
21. McCormick C, Leduc Y, Martindale D, et al. The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet. 1998;19(2):158-161.
22. Rozemuller H, van der Spek E, Bogers-Boer LH, et al. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus- myeloma effect. Haematologica. 2008;93(7): 1049-1057.
23. -/- mice. Methods Mol Biol. 2008;415:65-82.
24. -/- double-mutant mice. Blood. 2003;102(7):2522-2531.
25. Traggiai E, Chicha L, Mazzucchelli L, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science. 2004; 304(5667):104-107.